|
Daniel Glassman is Chairman of the Board and Chief Executive Officer of Bradley Pharmaceuticals, Inc. Mr. Glassman founded Bradley in January 1985. Mr. Glassman was the key force that took the Company public as a NASDAQ traded corporation in November 1991 and drove the transition to the New York Stock Exchange as of May 13, 2003. Mr. Glassman also is Chairman of the Board and Chief Executive Officer of Doak Dermatologics, Bradley Pharmaceuticals (Canada), Inc., and Bradley Pharmaceuticals, Overseas, Ltd., Inc., each a subsidiary of Bradley Pharmaceuticals, Inc.
Mr. Glassman has thirty-two years experience in pharmaceutical management and healthcare communications. He is actively involved in the development of medical education programs for numerous pharmaceutical and medical professional associations. Mr. Glassman is an associate member of the American Academy of Dermatology, a member of the University Advisory Committee, Long Island University Health Sciences, as well as a lecturer, publisher and author. He has been named the Ernst & Young LLP Entrepreneur of the Year (1995) in the New Jersey Life Sciences division.
| 
